Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats

J Immunol. 2000 Mar 1;164(5):2650-9. doi: 10.4049/jimmunol.164.5.2650.

Abstract

The role of the CC chemokines, macrophage inflammatory protein-1 beta (MIP-1 beta), monocyte chemotactic peptide-1 (MCP-1), and RANTES, in acute lung inflammatory injury induced by intrapulmonary deposition of IgG immune complexes injury in rats was determined. Rat MIP-1 beta, MCP-1, and RANTES were cloned, the proteins were expressed, and neutralizing Abs were developed. mRNA and protein expression for MIP-1 beta and MCP-1 were up-regulated during the inflammatory response, while mRNA and protein expression for RANTES were constitutive and unchanged during the inflammatory response. Treatment of rats with anti-MIP-1 beta Ab significantly decreased vascular permeability by 37% (p = 0.012), reduced neutrophil recruitment into lung by 65% (p = 0.047), and suppressed levels of TNF-alpha in bronchoalveolar lavage fluids by 61% (p = 0.008). Treatment of rats with anti-rat MCP-1 or anti-rat RANTES had no effect on the development of lung injury. In animals pretreated intratracheally with blocking Abs to MCP-1, RANTES, or MIP-1 beta, significant reductions in the bronchoalveolar lavage content of these chemokines occurred, suggesting that these Abs had reached their targets. Conversely, exogenously MIP-1 beta, but not RANTES or MCP-1, caused enhancement of the lung vascular leak. These data indicate that MIP-1 beta, but not MCP-1 or RANTES, plays an important role in intrapulmonary recruitment of neutrophils and development of lung injury in the model employed. The findings suggest that in chemokine-dependent inflammatory responses in lung CC chemokines do not necessarily demonstrate redundant function.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Disease
  • Animals
  • Antibodies, Blocking / administration & dosage
  • Antigen-Antibody Complex / toxicity
  • Bronchoalveolar Lavage Fluid / immunology
  • Chemokine CCL2 / administration & dosage
  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / physiology*
  • Chemokine CCL4
  • Chemokine CCL5 / administration & dosage
  • Chemokine CCL5 / antagonists & inhibitors
  • Chemokine CCL5 / genetics
  • Chemokine CCL5 / physiology*
  • Chemokines, CC / administration & dosage
  • Chemokines, CC / antagonists & inhibitors
  • Chemokines, CC / genetics
  • Chemokines, CC / physiology*
  • Chemotaxis, Leukocyte / immunology
  • Cloning, Molecular
  • Immune Sera / administration & dosage
  • Immunoglobulin G / toxicity
  • Intubation, Intratracheal
  • Lung / immunology*
  • Lung / metabolism
  • Lung / pathology*
  • Macrophage Inflammatory Proteins / administration & dosage
  • Macrophage Inflammatory Proteins / antagonists & inhibitors
  • Macrophage Inflammatory Proteins / genetics
  • Macrophage Inflammatory Proteins / physiology*
  • Male
  • Pulmonary Alveoli / immunology
  • Pulmonary Alveoli / pathology
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Long-Evans
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / immunology

Substances

  • Antibodies, Blocking
  • Antigen-Antibody Complex
  • Chemokine CCL2
  • Chemokine CCL4
  • Chemokine CCL5
  • Chemokines, CC
  • Immune Sera
  • Immunoglobulin G
  • Macrophage Inflammatory Proteins
  • RNA, Messenger
  • Recombinant Proteins